Transtek(SZ:300562) Xin Lang Cai Jing·2025-08-18 01:43Core Insights - Le Xin Medical (300562.SZ) reported a total operating revenue of 521 million yuan for the first half of 2025, an increase of 22.77 million yuan compared to the same period last year, marking a year-on-year growth of 4.57% [1] - The net profit attributable to shareholders reached 42.29 million yuan, up by 7.44 million yuan year-on-year, achieving a growth of 21.35% compared to the same period last year [1] - The net cash inflow from operating activities was 48.25 million yuan, an increase of 15.38 million yuan year-on-year, reflecting a growth of 46.80% [1] Financial Performance - The latest debt-to-asset ratio stands at 33.31%, a decrease of 1.64 percentage points from the previous quarter and a reduction of 2.67 percentage points compared to the same period last year [3] - The latest gross profit margin is 35.00% [3] - The return on equity (ROE) is 4.19%, an increase of 0.82 percentage points year-on-year [3] - The diluted earnings per share (EPS) is 0.19 yuan, an increase of 0.03 yuan year-on-year, reflecting a growth of 21.03% [3] - The total asset turnover ratio is 0.35 times, an increase of 0.03 times year-on-year, marking a growth of 9.78% [3] - The inventory turnover ratio is 4.06 times, an increase of 0.58 times year-on-year, reflecting a growth of 16.74% [3] Shareholder Structure - The number of shareholders is 25,700, with the top ten shareholders holding a total of 78.08 million shares, accounting for 35.89% of the total share capital [3] - The largest shareholder is Pan Weichao, holding 30.71% of the shares [3]